Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-06 08:30 |
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool t…
|
English | 384.7 KB | ||
| 2025-11-04 17:50 |
Transgene Provides Business and Financial Update for Q3 2025
|
English | 453.1 KB | ||
| 2025-11-04 17:50 |
Transgene fait le point sur ses activités et sa situation financière au troisiè…
|
French | 345.9 KB | ||
| 2025-11-04 17:45 |
New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potentia…
|
English | 451.7 KB | ||
| 2025-11-04 17:45 |
Les nouvelles données d’immunologie de la Phase I de TG4050 présentées au SITC …
|
French | 447.9 KB | ||
| 2025-10-20 08:30 |
Le virus oncolytique armé BT-001, développé par Transgene et BioInvent, montre …
|
French | 406.5 KB | ||
| 2025-10-20 08:30 |
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Ab…
|
English | 400.4 KB | ||
| 2025-10-13 08:30 |
Transgene et BioInvent présentent des données translationnelles et la mise à j…
|
French | 399.0 KB | ||
| 2025-10-13 08:30 |
Transgene and BioInvent to Present Translational Data and Updated Clinical Resu…
|
English | 413.4 KB | ||
| 2025-10-03 17:45 |
Transgene présente de nouvelles données d’immunologie de la Phase I de TG4050, …
|
French | 405.9 KB | ||
| 2025-10-03 17:45 |
Transgene to Present New Immunological Data from Phase I Trial of Individualize…
|
English | 396.4 KB | ||
| 2025-09-16 17:45 |
RAPPORT SEMESTRIEL 2025
|
French | 1.0 MB | ||
| 2025-09-16 17:45 |
2025 Half-year financial information
|
English | 1.0 MB | ||
| 2025-09-16 17:45 |
Données positives de la Phase I randomisée de TG4050, vaccin thérapeutique indi…
|
French | 684.0 KB | ||
| 2025-09-16 17:45 |
Mise à disposition du Rapport Financier Semestriel au 30 juin 2025
|
French | 209.1 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
